Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Modern Pharmaceutical To Acquire Shanghai Institute Of Pharmaceutical Industry 

This article was originally published in PharmAsia News

Executive Summary

Shanghai Modern Pharmaceutical plans to acquire the stake of its biggest shareholder,Shanghai Institute of Pharmaceutical Industry. As one of the three largest state-owned listed companies in the pharmaceutical sector, Modern Pharmaceutical will get the equity injection from SIPI in accordance with State-owned Assets Supervision and Administration Commission of the State Council's direction of listing government-owned enterprises. SIPI, one of the most sizable and strongest domestic comprehensive research institutions, looks set to follow this strategy. If the reorganization is successful, Modern Pharmaceutical will become China's first listed state-owned firm, which integrates an academic institution, an industrial base and five national research centers. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel